- Home
- CFR vs LEGN Comparison
CFR vs LEGN Comparison
Compare CFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- LEGN
- Stock Information
- Founded
- CFR 1868
- LEGN 2014
- Country
- CFR United States
- LEGN United States
- Employees
- CFR N/A
- LEGN N/A
- Industry
- CFR Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CFR Finance
- LEGN Health Care
- Exchange
- CFR Nasdaq
- LEGN Nasdaq
- Market Cap
- CFR 7.9B
- LEGN 7.0B
- IPO Year
- CFR N/A
- LEGN 2020
- Fundamental
- Price
- CFR $130.21
- LEGN $27.80
- Analyst Decision
- CFR Hold
- LEGN Strong Buy
- Analyst Count
- CFR 15
- LEGN 13
- Target Price
- CFR $133.13
- LEGN $75.67
- AVG Volume (30 Days)
- CFR 385.6K
- LEGN 1.6M
- Earning Date
- CFR 05-01-2025
- LEGN 05-13-2025
- Dividend Yield
- CFR 3.07%
- LEGN N/A
- EPS Growth
- CFR 7.71
- LEGN N/A
- EPS
- CFR 9.11
- LEGN N/A
- Revenue
- CFR $2,038,108,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CFR $11.62
- LEGN $65.96
- Revenue Next Year
- CFR $3.90
- LEGN $52.55
- P/E Ratio
- CFR $14.29
- LEGN N/A
- Revenue Growth
- CFR 5.45
- LEGN 112.46
- 52 Week Low
- CFR $94.09
- LEGN $29.27
- 52 Week High
- CFR $147.64
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CFR 67.31
- LEGN 29.31
- Support Level
- CFR $129.05
- LEGN $30.25
- Resistance Level
- CFR $131.82
- LEGN $33.30
- Average True Range (ATR)
- CFR 2.57
- LEGN 1.72
- MACD
- CFR 1.65
- LEGN -0.41
- Stochastic Oscillator
- CFR 90.82
- LEGN 3.14
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.